Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy

Journal of Endocrinological Investigation

Volumn 38, Issue 7, 2015, Pages 769-777

  Ponto, K A ^a   Diana, T ^a   Binder, H ^a   Matheis, N ^a   Pitz, S ^a   Pfeiffer, N ^a   Kahaly, G J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Dysthyroid optic neuropathy; Thyroid eye disease; Thyroid stimulating immunoglobulins

Indexed keywords

THYROID STIMULATING IMMUNOGLOBULIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOCRINE OPHTHALMOPATHY; EVOKED VISUAL RESPONSE; EYE SWELLING; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPTIC DISK; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; SENSITIVITY AND SPECIFICITY; AGED; BLOOD;

AGED; BIOMARKERS; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; MALE; MIDDLE AGED;

EID: 84930912261     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-015-0254-2     Document Type: Article

References (57)

1. Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of Graves' disease: a 2014 update. J Endocrinol Invest 37(8):691-700. doi: 10.1007/s40618-014-0097-2
2. Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L (2013) Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98(4):1443-1449. doi: 10.1210/jc.2012-3873
3. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W (2011) Selenium and the course of mild Graves' orbitopathy. N Engl J Med 364(20):1920-1931. doi: 10.1056/NEJMoa1012985
4. Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L (2013) Prevalence and natural history of Graves' orbitopathy in the XXI century. J Endocrinol Invest 36(6):444-449. doi: 10.3275/8937
5. Bartley GB (1994) The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 92:477-588
6. Ebner R (2002) Dysthyroid optic neuropathy (DON). Semin Ophthalmol 17(1):18-21. doi: 10.1076/soph.17.1.18.10289
7. Neigel JM, Rootman J, Belkin RI, Nugent RA, Drance SM, Beattie CW, Spinelli JA (1988) Dysthyroid optic neuropathy. The crowded orbital apex syndrome. Ophthalmology 95(11):1515-1521
8. Du Y, Ye H, Li K, Xiao X, Chen R, He JF, Yang H (2014) Vision-related quality of life tends to be more severely impaired in patients with dysthyroid optic neuropathy. Curr Eye Res 39(5):532-536. doi: 10.3109/02713683.2013.848901
9. Ponto KA, Hommel G, Pitz S, Elflein H, Pfeiffer N, Kahaly GJ (2011) Quality of life in a german graves orbitopathy population. Am J Ophthalmol 152(3):483-490. doi: 10.1016/j.ajo.2011.02.018 (e481)
10. Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ (2013) Public health relevance of Graves' orbitopathy. J Clin Endocrinol Metab 98(1):145-152. doi: 10.1210/jc.2012-3119
11. Zang S, Ponto KA, Pitz S, Kahaly GJ (2011) Dose of intravenous steroids and therapy outcome in Graves' orbitopathy. J Endocrinol Invest 34(11):876-880
12. Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Curro N, Boschi A, Bernard M, von Arx G (2012) Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J Clin Endocrinol Metab 97(12):4454-4463. doi: 10.1210/jc.2012-2389
13. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM (2008) Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid Off J Am Thyroid Assoc 18(3):333-346. doi: 10.1089/thy.2007.0315
14. Choe CH, Cho RI, Elner VM (2011) Comparison of lateral and medial orbital decompression for the treatment of compressive optic neuropathy in thyroid eye disease. Ophthalmic Plast Reconstr Surg 27(1):4-11. doi: 10.1097/IOP.0b013e3181df6a87
15. Guy JR, Fagien S, Donovan JP, Rubin ML (1989) Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy. Ophthalmology 96(7):1048-1052 (discussion 1052-1043)
16. Kazim M, Trokel S, Moore S (1991) Treatment of acute Graves orbitopathy. Ophthalmology 98(9):1443-1448
17. Leone CR Jr, Bajandas FJ (1981) Inferior orbital decompression for dysthyroid optic neuropathy. Ophthalmology 88(6):525-532
18. Panzo GJ, Tomsak RL (1983) A retrospective review of 26 cases of dysthyroid optic neuropathy. Am J Ophthalmol 96(2):190-194
19. Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96(2):320-332. doi: 10.1210/jc.2010-1962
20. Tanda ML, Piantanida E, Bartalena L (2012) Treating Graves' orbitopathy: where are we? Endocrine 41(2):167-168. doi: 10.1007/s12020-012-9607-1
21. Bartalena L, Lai A, Compri E, Marcocci C, Tanda ML (2008) Novel immunomodulating agents for Graves orbitopathy. Ophthalmic Plast Reconstr Surg 24(4):251-256. doi: 10.1097/IOP.0b013e318179f8a5
22. Bartalena L, Lai A, Sassi L, Lombardi V, Dalle Mule I, Gandolfo M, Liparulo L, Azzolini C, Piantanida E, Tanda ML (2010) Novel treatment modalities for Graves' orbitopathy. Pediatr Endocrinol Rev PER 7(Suppl 2):210-216
23. Bartalena L, Tanda ML (2006) Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying. J Endocrinol Invest 29(11):1012-1016
24. Mourits MP, Bijl H, Altea MA, Baldeschi L, Boboridis K, Curro N, Dickinson AJ, Eckstein A, Freidel M, Guastella C, Kahaly GJ, Kalmann R, Krassas GE, Lane CM, Lareida J, Marcocci C, Marino M, Nardi M, Mohr C, Neoh C, Pinchera A, Orgiazzi J, Pitz S, Saeed P, Salvi M, Sellari-Franceschini S, Stahl M, von Arx G, Wiersinga WM (2009) Outcome of orbital decompression for disfiguring proptosis in patients with Graves' orbitopathy using various surgical procedures. Br J Ophthalmol 93(11):1518-1523. doi: 10.1136/bjo.2008.149302
25. Dayan CM, Dayan MR (2007) Dysthyroid optic neuropathy: a clinical diagnosis or a definable entity? Br J Ophthalmol 91(4):409-410. doi: 10.1136/bjo.2006.110932
26. da Silva FL, de Lourdes Veronese Rodrigues M, Akaishi PM, Cruz AA (2009) Graves' orbitopathy: frequency of ocular hypertension and glaucoma. Eye (London, England) 23(4):957-959. doi: 10.1038/eye.2008.155
27. McKeag D, Lane C, Lazarus JH, Baldeschi L, Boboridis K, Dickinson AJ, Hullo AI, Kahaly G, Krassas G, Marcocci C, Marino M, Mourits MP, Nardi M, Neoh C, Orgiazzi J, Perros P, Pinchera A, Pitz S, Prummel MF, Sartini MS, Wiersinga WM (2007) Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. Br J Ophthalmol 91(4):455-458. doi: 10.1136/bjo.2006.094607
28. Mensah A, Vignal-Clermont C, Mehanna C, Morel X, Galatoire O, Jacomet PV, Morax S (2009) Dysthyroid optic neuropathy: atypical initial presentation and persistent visual loss. Orbit (Amsterdam, Netherlands) 28(6):354-362. doi: 10.3109/01676830903104728
29. Bartley GB, Gorman CA (1995) Diagnostic criteria for Graves' ophthalmopathy. Am J Ophthalmol 119(6):792-795
30. Lipski A, Eckstein A, Esser J, Loesch C, Mann K, Mohr C, Jurklies B (2011) Course of pattern-reversed visual evoked cortical potentials in 30 eyes after bony orbital decompression in dysthyroid optic neuropathy. Br J Ophthalmol 95(2):222-226. doi: 10.1136/bjo.2009.173658
31. Perez-Rico C, Rodriguez-Gonzalez N, Arevalo-Serrano J, Blanco R (2012) Evaluation of multifocal visual evoked potentials in patients with Graves' orbitopathy and subclinical optic nerve involvement. Doc Ophthalmol Adv Ophthalmol 125(1):11-19. doi: 10.1007/s10633-012-9325-2
32. Weis E, Heran MK, Jhamb A, Chan AK, Chiu JP, Hurley MC, Rootman J (2011) Clinical and soft-tissue computed tomographic predictors of dysthyroid optic neuropathy: refinement of the constellation of findings at presentation. Arch Ophthalmol 129(10):1332-1336. doi: 10.1001/archophthalmol.2011.276
33. Weis E, Heran MK, Jhamb A, Chan AK, Chiu JP, Hurley MC, Rootman J (2012) Quantitative computed tomographic predictors of compressive optic neuropathy in patients with thyroid orbitopathy: a volumetric analysis. Ophthalmology 119(10):2174-2178. doi: 10.1016/j.ophtha.2012.04.021
34. Dragan LR, Seiff SR, Lee DC (2006) Longitudinal correlation of thyroid-stimulating immunoglobulin with clinical activity of disease in thyroid-associated orbitopathy. Ophthalmic Plast Reconstr Surg 22(1):13-19
35. Eckstein A, Esser J, Mann K, Schott M (2010) Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy. Pediatr Endocrinol Rev PER 7(Suppl 2):198-203
36. Kahaly G, Grubl M, Moncayo R, Schilling S, Weber P, Beyer J, Krause U (1989) Thyroid-stimulating and eye muscle antibodies in Graves' disease and Graves' orbitopathy. Dev Ophthalmol 20:68-78
37. Kahaly G, Moncayo R, Stover C, Beyer J (1991) Relationship of eye muscle antibodies with HLA phenotypes and thyroid-stimulating immunoglobulins in endocrine orbitopathy. Res Exp Med Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie 191(2):137-144
38. Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ (2010) A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. J Clin Endocrinol Metab 95(5):2123-2131. doi: 10.1210/jc.2009-2470
39. Ponto KA, Kanitz M, Olivo PD, Pitz S, Pfeiffer N, Kahaly GJ (2011) Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy. Ophthalmology 118(11):2279-2285. doi: 10.1016/j.ophtha.2011.03.030
40. Diana T, Brown RS, Bossowski A, Segni M, Niedziela M, Konig J, Bossowska A, Ziora K, Hale A, Smith J, Pitz S, Kanitz M, Kahaly GJ (2014) Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves' disease-A multicenter study. J Clin Endocrinol Metab 99(5):1648-1655. doi: 10.1210/jc.2013-4026
41. Diana T, Kanitz M, Lehmann M, Li Y, Olivo PD, Kahaly GJ (2014) Standardization of a bioassay for thyrotropin receptor stimulating autoantibodies. Thyroid Off J Am Thyroid Assoc. doi: 10.1089/thy.2014.0346
42. Kamijo K, Murayama H, Uzu T, Togashi K, Kahaly GJ (2010) A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells. Thyroid Off J Am Thyroid Assoc 20(8):851-856. doi: 10.1089/thy.2010.0059
43. Kamijo K, Murayama H, Uzu T, Togashi K, Olivo PD, Kahaly GJ (2011) Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease. Thyroid Off J Am Thyroid Assoc 21(12):1295-1299. doi: 10.1089/thy.2011.0056
44. Leschik JJ, Diana T, Olivo PD, Konig J, Krahn U, Li Y, Kanitz M, Kahaly GJ (2013) Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol 139(2):192-200. doi: 10.1309/ajcpzut7cnueu7op
45. Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, Boschi A, Dickinson AJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marino M, Nardi M, Neoh C, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Sartini MS, Stahl M, von Arx G (2006) Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol/European Fed Endocr Soc 155(3):387-389. doi: 10.1530/eje.1.02230
46. Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, Steuhl KP, Esser J, Morgenthaler NG (2004) Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol 61(5):612-618. doi: 10.1111/j.1365-2265.2004.02143.x
47. Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF (2000) Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol 52(3):267-271
48. Subekti I, Boedisantoso A, Moeloek ND, Waspadji S, Mansyur M (2012) Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy. Acta medica Indonesiana 44(2):114-121
49. Bai Y, Dai WX, Sun ML, Guo ZS, Jin X, Chi ZS (1987) Changes of serum TSI in hyperthyroidism with long-term antithyroid therapy. Proc Chin Acad Med Sci Peking Union Med Coll = Chung-kuo i hsueh k'o hsueh yuan, Chung-kuo hsieh ho i k'o ta hsueh hsueh pao 2(3):172-174
50. Kautbally S, Alexopoulou O, Daumerie C, Jamar F, Mourad M, Maiter D (2012) Greater efficacy of total thyroidectomy versus radioiodine therapy on hyperthyroidism and thyroid-stimulating immunoglobulin levels in patients with Graves' disease previously treated with antithyroid drugs. Eur Thyroid J 1(2):122-128. doi: 10.1159/000339473
51. Prentice MG, Rayman GA, Alaghband-Zadeh J, Wise PH (1987) Thyroid stimulating immunoglobulin bioactivity during carbimazole therapy as measured by the cytochemical bioassay. J Endocrinol Invest 10(5):483-489
52. Rittmaster RS, Zwicker H, Abbott EC, Douglas R, Givner ML, Gupta MK, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE (1996) Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease. J Clin Endocrinol Metab 81(9):3283-3288. doi: 10.1210/jcem.81.9.8784084
53. Szabo J, Leovey A, Karanyi Z, Varvolgyi C, Forizs E, Herceg L (1989) Detectability of thyroid anti-microsomal antibodies, changes in thyroid-stimulating immunoglobulins (TSI) and thyrotropin-binding-inhibiting immunoglobulins (TBII) during methimazole treatment of Graves' disease patients. Acta Med Hung 46(1):23-30
54. Ponto KA, Zang S, Kahaly GJ (2010) The tale of radioiodine and Graves' orbitopathy. Thyroid Off J Am Thyroid Assoc 20(7):785-793. doi: 10.1089/thy.2010.1640
55. Vannucchi G, Campi I, Covelli D, Dazzi D, Curro N, Simonetta S, Ratiglia R, Beck-Peccoz P, Salvi M (2009) Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 94(9):3381-3386. doi: 10.1210/jc.2009-0506
56. Michelangeli VP, Poon C, Topliss DJ, Colman PG (1995) Specific effects of radioiodine treatment on TSAb and TBAb levels in patients with Graves' disease. Thyroid Off J Am Thyroid Assoc 5(3):171-176
57. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O (2008) TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol/Eur Fed Endocr Soc 158(1):69-75. doi: 10.1530/eje-07-0450